health 𧬠New drug Jideytro approved for lung cancer patients
The FDA has approved Jideytro, which is zidesamtinib, for adults with advanced ROS1-positive non-small cell lung cancer. This treatment is specifically for patients whose cancer has already responded to a ROS1 inhibitor. The ARROS-1 phase I/II study showed a 44% objective response rate in the overall population. Notably, the drug also showed activity in patients with brain metastases and ROS1 resistance mutations. Experts view this approval as significant progress for those with limited treatment options. π§¬